Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.

The USPTO has given the WYOST trademark a serial number of 79324787. The federal status of this trademark filing is REGISTERED as of Tuesday, May 24, 2022. This trademark is owned by Novartis AG.

The WYOST. Explore trademark details, ownership information, other trademarks owned by Novartis AG or file your own trademark. Trademarkia provides a free, fast, user friendly search of USPTO registered trademarks.

Summary Basis of Decision for Wyost: The Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations. Report a serious adverse drug reaction (for hospitals)

Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone. Below package inserts are available for further reading: This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

2024年3月14日 · 3月5日，FDA批准Jubbonti注射剂作为美国许可的Prolia的可互换生物仿制药，批准Wyost注射剂作为美国许可的Xgeva的可互换生物仿制药。 两种生物仿制药与各自的参考药物具有相同的剂型、给药方案、给药途径和适应症。

2024年5月29日 · Wyost (denosumab-bbdz) is an injection that is administered subcutaneously (under the skin) by a healthcare provider for the: Treatment of high calcium levels associated with cancer (hypercalcemia of malignancy) that has not responded to bisphosphonates.

Wyost (denosumab-bbdz) injection is a sterile, preservative-free, clear to slightly opalescent and colorless to slightly yellowish to slightly brownish solution for subcutaneous use.

WYOST Solution for injection Ref.[110543] Active ingredients: Denosumab. Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Sandoz GmbH, Biochemiestr. 10, 6250 Kundl, Austria

WYOST Novartis AG. USPTO Trademarks › Novartis AG › Wyost Application #79324787. Trademark Registered: 2022-05-24. Trademark Application Details. Status Refresh. 630. Live/Pending. NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER. Research: OneLook Acronym Finder; Serial Number: 79324787: